REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 161 filers reported holding REATA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.49 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $31,746,062 | +118.5% | 311,358 | +94.8% | 0.15% | +108.3% |
| Q1 2023 | $14,530,471 | +75.6% | 159,816 | -26.6% | 0.07% | +56.5% |
| Q4 2022 | $8,276,008 | +3.0% | 217,847 | -31.9% | 0.05% | +7.0% |
| Q3 2022 | $8,036,000 | +20.8% | 319,780 | +46.1% | 0.04% | +26.5% |
| Q2 2022 | $6,651,000 | -20.2% | 218,853 | -13.9% | 0.03% | -27.7% |
| Q1 2022 | $8,331,000 | -2.1% | 254,305 | -21.2% | 0.05% | 0.0% |
| Q4 2021 | $8,507,000 | -15.3% | 322,586 | +354.4% | 0.05% | -32.9% |
| Q2 2021 | $10,047,000 | +503.8% | 70,990 | +325.4% | 0.07% | +483.3% |
| Q1 2021 | $1,664,000 | +300.0% | 16,689 | +479.5% | 0.01% | 0.0% |
| Q1 2020 | $416,000 | -86.0% | 2,880 | -80.2% | 0.01% | -79.3% |
| Q4 2019 | $2,971,000 | +558.8% | 14,532 | +175.6% | 0.06% | +314.3% |
| Q1 2019 | $451,000 | – | 5,272 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |